Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 800 entries
Sorted by: Best Match Show Resources per page
Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study.

Current therapeutic research, clinical and experimental

Palacios R, Santos J, Camino X, Arazo P, Torres Perea R, Echevarrfa S, Ribera E, Sánchez de la Rosa R, Moreno Guillen S.
PMID: 24672118
Curr Ther Res Clin Exp. 2005 Mar;66(2):117-29. doi: 10.1016/j.curtheres.2005.04.002.

BACKGROUND: The Recover Study is an ongoing, prospective study designed 10 to assess toxicity associated with the use of nucleoside analogue reverse transcriptase inhibitors (NRTIs) (stavudine, zidovudine, lamivudine, didanosine, abacavir) in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART)...

Cite
Palacios R, Santos J, Camino X, et al. Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Curr Ther Res Clin Exp. 2005;66(2):117-29doi: 10.1016/j.curtheres.2005.04.002.
Palacios, R., Santos, J., Camino, X., Arazo, P., Torres Perea, R., Echevarrfa, S., Ribera, E., Sánchez de la Rosa, R., Moreno Guillen, S. (2005). Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Current therapeutic research, clinical and experimental, 66(2), 117-29. https://doi.org/10.1016/j.curtheres.2005.04.002
Palacios, Rosario, et al. "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study." Current therapeutic research, clinical and experimental vol. 66,2 (2005): 117-29. doi: https://doi.org/10.1016/j.curtheres.2005.04.002
Palacios R, Santos J, Camino X, Arazo P, Torres Perea R, Echevarrfa S, Ribera E, Sánchez de la Rosa R, Moreno Guillen S. Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Curr Ther Res Clin Exp. 2005 Mar;66(2):117-29. doi: 10.1016/j.curtheres.2005.04.002. PMID: 24672118; PMCID: PMC3964549.
Copy Download .nbib Format: NLM
[In Process Citation].

Orvosi hetilap

Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Tornai I, Werling K, Hunyady B.
PMID: 26667112
Orv Hetil. 2015 Dec 15;156:25-36. doi: 10.1556/OH.2015.30331.

Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further...

Cite
Horváth G, Gerlei Z, Gervain J, et al. A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orv Hetil. 2015;156:25-36doi: 10.1556/OH.2015.30331.
Horváth, G., Gerlei, Z., Gervain, J., Lengyel, G., Makara, M., Pár, A., Rókusz, L., Szalay, F., Tornai, I., Werling, K., & Hunyady, B. (2015). A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orvosi hetilap, 15625-36. https://doi.org/10.1556/OH.2015.30331
Horváth, Gábor, et al. "A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től." [In Process Citation]. Orvosi hetilap vol. 156 (2015): 25-36. doi: https://doi.org/10.1556/OH.2015.30331
Horváth G, Gerlei Z, Gervain J, Lengyel G, Makara M, Pár A, Rókusz L, Szalay F, Tornai I, Werling K, Hunyady B. A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2015. szeptember 12-től. [In Process Citation]. Orv Hetil. 2015 Dec 15;156:25-36. doi: 10.1556/OH.2015.30331. Hungarian. PMID: 26667112.
Copy Download .nbib Format: NLM
Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis.

Gastroenterology research and practice

Wang HL, Lu X, Yang X, Xu N.
PMID: 27672391
Gastroenterol Res Pract. 2016;2016:3435965. doi: 10.1155/2016/3435965. Epub 2016 Sep 08.

The relative efficacy of different strategies for chronic hepatitis B (CHB) patients with lamivudine resistance (LAM-R) has not yet been systematically studied. Clinical trials were searched in PUBMED, MEDLINE, EMBASE, and CNKI databases up to February 15, 2016. Nine...

Cite
Wang HL, Lu X, Yang X, et al. Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis. Gastroenterol Res Pract. 2016;2016:3435965doi: 10.1155/2016/3435965.
Wang, H. L., Lu, X., Yang, X., & Xu, N. (2016). Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis. Gastroenterology research and practice, 20163435965. https://doi.org/10.1155/2016/3435965
Wang, Hui-Lian, et al. "Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis." Gastroenterology research and practice vol. 2016 (2016): 3435965. doi: https://doi.org/10.1155/2016/3435965
Wang HL, Lu X, Yang X, Xu N. Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis. Gastroenterol Res Pract. 2016;2016:3435965. doi: 10.1155/2016/3435965. Epub 2016 Sep 08. PMID: 27672391; PMCID: PMC5031861.
Copy Download .nbib Format: NLM
Hepatitis B in patients with hematological diseases: An update.

World journal of hepatology

Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M.
PMID: 28951776
World J Hepatol. 2017 Sep 08;9(25):1043-1053. doi: 10.4254/wjh.v9.i25.1043.

Hepatitis B virus (HBV) reactivation (HBVr) in patients undergoing immunosuppressive therapy is still a hot topic worldwide. Its prevention and management still represents a challenge for specialists dealing with immunosuppressed patients. Aim of this paper is to provide a...

Cite
Coluccio C, Begini P, Marzano A, et al. Hepatitis B in patients with hematological diseases: An update. World J Hepatol. 2017;9(25):1043-1053doi: 10.4254/wjh.v9.i25.1043.
Coluccio, C., Begini, P., Marzano, A., Pellicelli, A., Imperatrice, B., Anania, G., Delle Fave, G., & Marignani, M. (2017). Hepatitis B in patients with hematological diseases: An update. World journal of hepatology, 9(25), 1043-1053. https://doi.org/10.4254/wjh.v9.i25.1043
Coluccio, Chiara, et al. "Hepatitis B in patients with hematological diseases: An update." World journal of hepatology vol. 9,25 (2017): 1043-1053. doi: https://doi.org/10.4254/wjh.v9.i25.1043
Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol. 2017 Sep 08;9(25):1043-1053. doi: 10.4254/wjh.v9.i25.1043. PMID: 28951776; PMCID: PMC5596311.
Copy Download .nbib Format: NLM
Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation.

Patient related outcome measures

Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C.
PMID: 25733942
Patient Relat Outcome Meas. 2015 Feb 17;6:53-60. doi: 10.2147/PROM.S63586. eCollection 2015.

OBJECTIVES: Costs may play a role in deciding how and when to start highly active antiretroviral therapy (HAART) in a naïve patient. The aim of the present study was to assess the cost- effectiveness of treatment with HAART in...

Cite
Maggiolo F, Colombo GL, Di Matteo S, et al. Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Relat Outcome Meas. 2015;6:53-60doi: 10.2147/PROM.S63586.
Maggiolo, F., Colombo, G. L., Di Matteo, S., Bruno, G. M., Astuti, N., Di Filippo, E., Masini, G., & Bernardini, C. (2015). Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient related outcome measures, 653-60. https://doi.org/10.2147/PROM.S63586
Maggiolo, Franco, et al. "Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation." Patient related outcome measures vol. 6 (2015): 53-60. doi: https://doi.org/10.2147/PROM.S63586
Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C. Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Relat Outcome Meas. 2015 Feb 17;6:53-60. doi: 10.2147/PROM.S63586. eCollection 2015. PMID: 25733942; PMCID: PMC4337626.
Copy Download .nbib Format: NLM
Circulating full-length cytokeratin 18 for predicting prognosis of hepatitis B virus-related acute-on-chronic liver failure patients with lamivudine treatment.

Hepatology research : the official journal of the Japan Society of Hepatology

Ding G, Li Z, Zhang L, Ma H, Li H.
PMID: 26138382
Hepatol Res. 2016 Apr;46(4):329-34. doi: 10.1111/hepr.12549. Epub 2015 Jul 27.

AIM: The predictive value of circulating full-length cytokeratin 18 (M65) on prognosis of hepatitis B virus-related liver failure is still not well investigated. The aim of this study was to reveal the association between serum M65 levels and outcomes...

Cite
Ding G, Li Z, Zhang L, et al. Circulating full-length cytokeratin 18 for predicting prognosis of hepatitis B virus-related acute-on-chronic liver failure patients with lamivudine treatment. Hepatol Res. 2015;46(4):329-34doi: 10.1111/hepr.12549.
Ding, G., Li, Z., Zhang, L., Ma, H., & Li, H. (2016). Circulating full-length cytokeratin 18 for predicting prognosis of hepatitis B virus-related acute-on-chronic liver failure patients with lamivudine treatment. Hepatology research : the official journal of the Japan Society of Hepatology, 46(4), 329-34. https://doi.org/10.1111/hepr.12549
Ding, Guofeng, et al. "Circulating full-length cytokeratin 18 for predicting prognosis of hepatitis B virus-related acute-on-chronic liver failure patients with lamivudine treatment." Hepatology research : the official journal of the Japan Society of Hepatology vol. 46,4 (2016): 329-34. doi: https://doi.org/10.1111/hepr.12549
Ding G, Li Z, Zhang L, Ma H, Li H. Circulating full-length cytokeratin 18 for predicting prognosis of hepatitis B virus-related acute-on-chronic liver failure patients with lamivudine treatment. Hepatol Res. 2016 Apr;46(4):329-34. doi: 10.1111/hepr.12549. Epub 2015 Jul 27. PMID: 26138382.
Copy Download .nbib Format: NLM
A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients.

Hepatology international

Chen CH, Hu TH, Hung CH, Lu SN, Wang JH, Chang MH, Changchien CS, Lee CM.
PMID: 26201920
Hepatol Int. 2013 Jul;7(3):832-43. doi: 10.1007/s12072-013-9440-5. Epub 2013 Jul 31.

PURPOSE: To compare the efficacy of entecavir (ETV) monotherapy up to 4 years in nucleos(t)ide analog (NA)-experienced and -naïve subjects.METHODS: One hundred sixty NA-experienced and 282 naïve chronic hepatitis B patients who were treated with ETV were enrolled. Of...

Cite
Chen CH, Hu TH, Hung CH, et al. A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients. Hepatol Int. 2013;7(3):832-43doi: 10.1007/s12072-013-9440-5.
Chen, C. H., Hu, T. H., Hung, C. H., Lu, S. N., Wang, J. H., Chang, M. H., Changchien, C. S., & Lee, C. M. (2013). A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients. Hepatology international, 7(3), 832-43. https://doi.org/10.1007/s12072-013-9440-5
Chen, Chien-Hung, et al. "A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients." Hepatology international vol. 7,3 (2013): 832-43. doi: https://doi.org/10.1007/s12072-013-9440-5
Chen CH, Hu TH, Hung CH, Lu SN, Wang JH, Chang MH, Changchien CS, Lee CM. A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients. Hepatol Int. 2013 Jul;7(3):832-43. doi: 10.1007/s12072-013-9440-5. Epub 2013 Jul 31. PMID: 26201920.
Copy Download .nbib Format: NLM
Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy.

F1000Research

Kakande B, Isaacs T, Muloiwa R, Dlamini S, Lehloenya R.
PMID: 26629333
F1000Res. 2015 Jun 30;4:175. doi: 10.12688/f1000research.6715.1. eCollection 2015.

A 31-year old HIV-infected African woman on nevirapine, tenofovir and lamivudine for more than 4 years presented with an 8-day history of symptoms and signs of Stevens-Johnson syndrome. She was on no other medication. Her viral load was undetectable...

Cite
Kakande B, Isaacs T, Muloiwa R, et al. Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy. F1000Res. 2015;4:175doi: 10.12688/f1000research.6715.1.
Kakande, B., Isaacs, T., Muloiwa, R., Dlamini, S., & Lehloenya, R. (2015). Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy. F1000Research, 4175. https://doi.org/10.12688/f1000research.6715.1
Kakande, Betty, et al. "Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy." F1000Research vol. 4 (2015): 175. doi: https://doi.org/10.12688/f1000research.6715.1
Kakande B, Isaacs T, Muloiwa R, Dlamini S, Lehloenya R. Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy. F1000Res. 2015 Jun 30;4:175. doi: 10.12688/f1000research.6715.1. eCollection 2015. PMID: 26629333; PMCID: PMC4642844.
Copy Download .nbib Format: NLM
The availability of six tracer medicines in private medicine outlets in Uganda.

Journal of pharmaceutical policy and practice

Birabwa C, Murison J, Evans V, Obua C, Agaba A, Waako P, Pollock A.
PMID: 25667747
J Pharm Policy Pract. 2014 Dec 08;7(1):18. doi: 10.1186/s40545-014-0018-y. eCollection 2014.

OBJECTIVES: Many low income countries struggle to provide safe and effective medicines due to poor public health care infrastructure, budgetary constraints, and lack of human resource capacity. Private sector pharmacies and drug shops are used by a majority of...

Cite
Birabwa C, Murison J, Evans V, et al. The availability of six tracer medicines in private medicine outlets in Uganda. J Pharm Policy Pract. 2014;7(1):18doi: 10.1186/s40545-014-0018-y.
Birabwa, C., Murison, J., Evans, V., Obua, C., Agaba, A., Waako, P., & Pollock, A. (2014). The availability of six tracer medicines in private medicine outlets in Uganda. Journal of pharmaceutical policy and practice, 7(1), 18. https://doi.org/10.1186/s40545-014-0018-y
Birabwa, Catherine, et al. "The availability of six tracer medicines in private medicine outlets in Uganda." Journal of pharmaceutical policy and practice vol. 7,1 (2014): 18. doi: https://doi.org/10.1186/s40545-014-0018-y
Birabwa C, Murison J, Evans V, Obua C, Agaba A, Waako P, Pollock A. The availability of six tracer medicines in private medicine outlets in Uganda. J Pharm Policy Pract. 2014 Dec 08;7(1):18. doi: 10.1186/s40545-014-0018-y. eCollection 2014. PMID: 25667747; PMCID: PMC4276013.
Copy Download .nbib Format: NLM
Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.

PloS one

Llibre JM, Raffi F, Moyle G, Behrens G, Bouee S, Reilly G, Borg P, Piontkowsky D, Rogatto F.
PMID: 27391807
PLoS One. 2016 Jul 08;11(7):e0159286. doi: 10.1371/journal.pone.0159286. eCollection 2016.

[This corrects the article DOI: 10.1371/journal.pone.0155406.].

Cite
Llibre JM, Raffi F, Moyle G, et al. Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. PLoS One. 2016;11(7):e0159286doi: 10.1371/journal.pone.0159286.
Llibre, J. M., Raffi, F., Moyle, G., Behrens, G., Bouee, S., Reilly, G., Borg, P., Piontkowsky, D., & Rogatto, F. (2016). Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. PloS one, 11(7), e0159286. https://doi.org/10.1371/journal.pone.0159286
Llibre, Josep M, et al. "Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy." PloS one vol. 11,7 (2016): e0159286. doi: https://doi.org/10.1371/journal.pone.0159286
Llibre JM, Raffi F, Moyle G, Behrens G, Bouee S, Reilly G, Borg P, Piontkowsky D, Rogatto F. Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. PLoS One. 2016 Jul 08;11(7):e0159286. doi: 10.1371/journal.pone.0159286. eCollection 2016. PMID: 27391807; PMCID: PMC4938098.
Copy Download .nbib Format: NLM
Cost of Treatment in HBeAg-Negative Chronic Hepatitis B Patients with 10-Years Projection Analysis.

The Eurasian journal of medicine

Karabay O, Ogutlu A, Guclu E.
PMID: 26180493
Eurasian J Med. 2015 Jun;47(2):99-103. doi: 10.5152/eurasianjmed.2015.052.

OBJECTIVE: Chronic hepatitis B infection has to be treated effectively due to its major complications. The aim of this study is to investigate and compare the therapy alternatives' treatment costs for hepatitis B e antigen (HBeAg) negative patients with...

Cite
Karabay O, Ogutlu A, Guclu E. Cost of Treatment in HBeAg-Negative Chronic Hepatitis B Patients with 10-Years Projection Analysis. Eurasian J Med. 2015;47(2):99-103doi: 10.5152/eurasianjmed.2015.052.
Karabay, O., Ogutlu, A., & Guclu, E. (2015). Cost of Treatment in HBeAg-Negative Chronic Hepatitis B Patients with 10-Years Projection Analysis. The Eurasian journal of medicine, 47(2), 99-103. https://doi.org/10.5152/eurasianjmed.2015.052
Karabay, Oguz, et al. "Cost of Treatment in HBeAg-Negative Chronic Hepatitis B Patients with 10-Years Projection Analysis." The Eurasian journal of medicine vol. 47,2 (2015): 99-103. doi: https://doi.org/10.5152/eurasianjmed.2015.052
Karabay O, Ogutlu A, Guclu E. Cost of Treatment in HBeAg-Negative Chronic Hepatitis B Patients with 10-Years Projection Analysis. Eurasian J Med. 2015 Jun;47(2):99-103. doi: 10.5152/eurasianjmed.2015.052. PMID: 26180493; PMCID: PMC4494558.
Copy Download .nbib Format: NLM
Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review.

Mediterranean journal of hematology and infectious diseases

Santorsola D, Abruzzese E.
PMID: 25745547
Mediterr J Hematol Infect Dis. 2015 Feb 15;7(1):e2015020. doi: 10.4084/MJHID.2015.020. eCollection 2015.

We report a case of a young patient with chronic viral hepatitis HBV infection, diagnosed with CML in March 2006 and treated with imatinib 400mg/die as first line therapy with concomitant Lamivudine. Patient obtained a complete hematologic response (CHR)...

Cite
Santorsola D, Abruzzese E. Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review. Mediterr J Hematol Infect Dis. 2015;7(1):e2015020doi: 10.4084/MJHID.2015.020.
Santorsola, D., & Abruzzese, E. (2015). Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review. Mediterranean journal of hematology and infectious diseases, 7(1), e2015020. https://doi.org/10.4084/MJHID.2015.020
Santorsola, Domenico, and Abruzzese, Elisabetta. "Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review." Mediterranean journal of hematology and infectious diseases vol. 7,1 (2015): e2015020. doi: https://doi.org/10.4084/MJHID.2015.020
Santorsola D, Abruzzese E. Successful Management of Pregnancy and Hepatic Toxicity in a CML Female Patient Treated with Nilotinib: a Case Report and a Review. Mediterr J Hematol Infect Dis. 2015 Feb 15;7(1):e2015020. doi: 10.4084/MJHID.2015.020. eCollection 2015. PMID: 25745547; PMCID: PMC4344172.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 800 entries